FCCC LOGO Faculty Publications
Davidson NE , Morrow M , Kopans DB , Koerner FC
Case 35-2005: A 56-year-old woman with breast cancer and isolated tumor cells in a sentinel lymph node
New England Journal of Medicine. 2005 ;353(20) :2177-2185
Back to previous list
00284793 (ISSN) Cited By: 0; Export Date: 25 May 2006; Source: Scopus CODEN: NEJMA Language of Original Document: English Correspondence Address: Davidson, N.E.; Johns Hopkins University; School of Medicine Baltimore, MD, United States Chemicals/CAS: tamoxifen, 10540-29-1, Antineoplastic Agents; Aromatase Inhibitors; Tamoxifen, 10540-29-1 References: Greene, F.L., Page, D.L., Fleming, I.D., (2002) AJCC Cancer Staging Manual. 6th Ed., New York: Springer-Verlag; Sobin, L.H., Wittekind, C., (2002) TNM: Classification of Malignant Tumours. 6th Ed., New York: Wiley-Liss; Singletary, S.E., Greene, F.L., Sobin, L.H., Classification of isolated tumor cells: Clarification of the 6th edition of the American Joint Committee on Cancer Staging Manual (2003) Cancer, 98, pp. 2740-2741; Carter, B.A., Jensen, R.A., Simpson, J.F., Page, D.L., Benign transport of breast epithelium into axillary lymph nodes after biopsy (2000) Am J Clin Pathol, 113, pp. 259-265; Wong, S.L., Edwards, M.J., Chao, C., Predicting the status of the nonsentinel axillary nodes: A multicenter study (2001) Arch Surg, 136, pp. 563-568; Chu, K.U., Turner, R.R., Hansen, N.M., Brennan, M.B., Giuliano, A.E., Sentinel node metastasis in patients with breast carcinoma accurately predicts immunohistochemically detectable nonsentinel node metastasis (1999) Ann Surg Oncol, 6, pp. 756-761; Nos, C., Harding-MacKean, C., Freneaux, P., Prediction of tumour involvement in remaining axillary lymph nodes when the sentinel node in a woman with breast cancer contains metastases (2003) Br J Surg, 90, pp. 1354-1360; Viale, G., Maiorano, E., Pruneri, G., Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy (2005) Ann Surg, 241, pp. 319-325; Van Zee, K.J., Manasseh, D.M., Bevilacqua, J.L., A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy (2003) Ann Surg Oncol, 10, pp. 1140-1151; Leidenius, M.H., Vironen, J.H., Riihela, M.S., The prevalence of non-sentinel node metastases in breast cancer patients with sentinel node micrometastases (2005) Eur J Surg Oncol, 31, pp. 13-18; Mignotte, H., Treilleux, I., Faure, C., Nessah, K., Bremond, A., Axillary lymph-node dissection for positive sentinel nodes in breast cancer patients (2002) Eur J Surg Oncol, 28, pp. 623-626; Kamath, V.J., Giuliano, R., Dauway, E.L., Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla: A study to evaluate the need for complete axillary lymph node dissection (2001) Arch Surg, 136, pp. 688-692; Hwang, R.F., Krishnamurthy, S., Hunt, K.K., Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer (2003) Ann Surg Oncol, 10, pp. 248-254; Menes, T.S., Tartter, P.I., Mizrachi, H., Constantino, J., Estabrook, A., Smith, S.R., Breast cancer patients with pN0(i+) and pN1(mi) sentinel nodes have high rate of nonsentinel node metastases (2005) J Am Coll Surg, 200, pp. 323-327; Goyal, A., Douglas-Jones, A., Newcombe, R.G., Mansel, R.E., Predictors of non-sentinel lymph node metastasis in breast cancer patients (2004) Eur J Cancer, 40, pp. 1731-1737; Travagli, J.P., Atallah, D., Mathieu, M.C., Sentinel lymphadenectomy without systematic axillary dissection in breast cancer patients: Predictors of non-sentinel lymph node metastasis (2003) Eur J Surg Oncol, 29, pp. 403-406; Fournier, K., Schiller, A., Perry, R.R., Laronga, C., Micrometastasis in the sentinel lymph node of breast cancer does not mandate completion axillary dissection (2004) Ann Surg, 239, pp. 859-863; Sachdev, U., Murphy, K., Derzie, A., Jaffer, S., Bleiweiss, I.J., Brower, S., Predictors of nonsentinel lymph node metastasis in breast cancer patients (2002) Am J Surg, 183, pp. 213-217; Lambert, L., Hunt, K.K., Hwang, R.F., Validation of a breast cancer nomogram for predicting additional nodal metastases after positive sentinel node biopsy (2005) Ann Surg Oncol, 12 (1 SUPPL.), pp. S17, abstract; Langer, I., Marti, W.R., Guller, U., Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: Prospective analysis of 150 patients after SLN biopsy (2005) Ann Surg, 241, pp. 152-158; Fant, J.S., Grant, M.D., Knox, S.M., Preliminary outcome analysis in patients with breast cancer and a positive sentinel lymph node who declined axillary dissection (2003) Ann Surg Oncol, 10, pp. 126-130; Guenther, J.M., Hansen, N.M., DiFronzo, L.A., Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes (2003) Arch Surg, 138, pp. 52-56; Greco, M., Agresti, R., Cascinelli, N., Breast cancer patients treated without axillary surgery: Clinical implications and biologic analysis (2000) Ann Surg, 232, pp. 1-7; Holmberg, S.B., Crivellari, D., Zahrieh, J., A randomized trial comparing axillary clearance versus no axillary clearance in patients older than 60 years with breast cancer: First results of International Breast Cancer Study Group Trial 10-93 (2004) J Clin Oncol, 22 (SUPPL.), pp. 4S, abstract; Fisher, B., Anderson, S., Bryant, J., Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer (2002) N Engl J Med, 347, pp. 1233-1241; Overgaard, M., Hansen, P.S., Overgaard, J., Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy: Danish Breast Cancer Cooperative Group 82b Trial (1997) N Engl J Med, 337, pp. 949-955; Overgaard, M., Jensen, M.B., Overgaard, J., Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial (1999) Lancet, 353, pp. 1641-1648; Louis-Sylvestre, C., Clough, K., Asselain, B., Axillary treatment in conservative management of operable breast cancer: Dissection or radiotherapy? Results of a randomized study with 15 years of follow-up (2004) J Clin Oncol, 22, pp. 97-101; Kaae, S., Johansen, H., Does simple mastectomy followed by irradiation offer survival comparable to radical procedures? (1977) Int J Radiat Oncol Biol Phys, 2, pp. 1163-1166; Langlands, A.O., Prescott, R.J., Hamilton, T., A clinical trial in the management of operable cancer of the breast (1980) Br J Surg, 67, pp. 170-174; Atkins, H., Hayward, J.L., Klugman, D.J., Wayte, A.B., Treatment of early breast cancer: A report after ten years of a clinical trial (1972) BMJ, 2, pp. 423-429; Hayward, J.L., The Guy's trial of treatments of "early" breast cancer (1977) World J Surg, 1, pp. 314-316; Orr, R.K., The impact of prophylactic axillary node dissection on breast cancer survival - A Bayesian meta-analysis (1999) Ann Surg Oncol, 6, pp. 109-116; Veronesi, U., Paganelli, G., Viale, G., A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer (2003) N Engl J Med, 349, pp. 546-553; Mansel, R.E., Goyal, A., Newcombe, R.G., Objective assessment of lymphedema, shoulder function and sensory deficit after sentinel node biopsy for invasive cancer: ALMANAC trial (2004) Breast Cancer Res Treat, 88 (1 SUPPL.), pp. S12, abstract; Galper, S., Recht, A., Silver, B., Factors associated with regional nodal failure in patients with early stage breast cancer with 0-3 positive axillary nodes following tangential irradiation alone (1999) Int J Radiat Oncol Biol Phys, 45, pp. 1157-1166; Hayes, D.F., Markers of increased risk for failure of adjuvant therapies (2003) Breast, 12, pp. 543-549; Quiet, C.A., Ferguson, D.J., Weichselbaum, R.R., Hellman, S., Natural history of node-negative breast cancer: A study of 826 patients with long-term follow-up (1995) J Clin Oncol, 13, pp. 1144-1151; Quiet, C.A., Ferguson, D.J., Weichselbaum, R.R., Hellman, S., Natural history of node-positive breast cancer: The curability of small cancers with a limited number of positive nodes (1996) J Clin Oncol, 14, pp. 3105-3111; Fisher, B., Bryant, J., Dignam, J., Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less (2002) J Clin Oncol, 20, pp. 4141-4149; Hansen, N.M., Grube, B.J., Te, W., Brennan, M.L., Turner, R., Guiliano, A.E., Clinical significance of axillary micrometastases in breast cancer: How small is too small? (2001) Proc Am Soc Clin Oncol, 20, pp. 24a, abstract; Kattan, M.W., Giri, D., Panageas, K.S., A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapy (2004) Cancer, 101, pp. 2509-2515; Paik, S., Shak, S., Tang, G., A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer (2004) N Engl J Med, 351, pp. 2817-2826; Paik, S., Shak, S., Tang, G., Expression of the 21 genes in the Recurrence Score assay and prediction of clinical benefit from tamoxifen in NSABP study B-14 and chemotherapy in NSABP study B-20 (2004) Proceedings of the 27th Annual San Antonio Breast Cancer Symposium, San Antonio, Tex., December 8-11, abstract; Goldhirsch, A., Glick, J.H., Gelber, R.D., Coates, A.S., Thurlimann, B., Senn, H.-J., Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005 (2005) Ann Oncol, 16, pp. 1569-1583; Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials (2005) Lancet, 365, pp. 1687-1717; Howell, A., Cuzick, J., Baum, M., Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer (2005) Lancet, 365, pp. 60-62; Thurlimann, B.J., Keshaviah, A., Mouridsen, J., BIG 1-98: Randomized double phase III study to evaluate letrozole (L) vs tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptorpositive breast cancer (2005) J Clin Oncol, 23, p. 65, abstract; Winer, E.P., Hudis, C., Burstein, H.J., American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004 (2005) J Clin Oncol, 23, pp. 619-629; Colleoni, M., Rotmensz, G., Peruzzotti, G., Size of breast cancer metastases in axillary lymph nodes: Clinical relevance of minimal lymph node involvement (2005) J Clin Oncol, 23, pp. 1379-1389; Ravdin, P.M., Siminoff, L.A., Davis, G.J., Computer program to assist in making decision about adjuvant therapy for women with early breast cancer (2001) J Clin Oncol, 19, pp. 980-991; Olivotto, I.A., Bajdik, C.D., Ravdin, P.M., Population-based validation of the prognostic model ADJUVANT! For early breast cancer (2005) J Clin Oncol, 23, pp. 2716-2725; Shapiro, C.L., Recht, A., Side effects of adjuvant treatment of breast cancer (2001) N Engl J Med, 344, pp. 1997-2008.